Form 4: Dyne Therapeutics Director Receives Stock Option Grant

Director Catherine Stehman-Breen was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of standard compensation.

Summary

• Director Catherine Stehman-Breen received a grant of 35,152 stock options on June 5, 2026.
• The options have an exercise price of $17.04 per share.
• The options are scheduled to vest in full on the earlier of June 5, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $17.04 exercise price.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 5, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Trading, Stock Options, Director Compensation